Bowen E F, Cherrington J M, Lamy P D, Griffiths P D, Johnson M A, Emery V C
Department of Virology, Royal Free and University College Medical School of University College London, England.
J Med Virol. 1999 Aug;58(4):402-7.
Five AIDS patients with cytomegalovirus (CMV) retinitis who had received ganciclovir (GCV) therapy were followed with serial blood sampling to detectchanges both in CMV load and in the genetic composition of genes UL97 and UL54 whilst receiving cidofovir (CDV) therapy. CDV neither reduced CMV load in blood nor prevented its quantitative resurgence during therapy. These effects were not explained by the initial presence or development of CDV-associated drug resistance mutations in UL54. In two patients, UL97 genotypic resistance to GCV involving either a L595S mutation or a deletion of amino acids 590-603 were present at the initiation of CDV and, in both patients, repopulation of CMV strains with wild-type UL97 sequences occurred during CDV therapy. These data are consistent with GCV-resistant strains containing UL97 mutations being less fit than their wild-type counterparts and so being able to persist only with the selective pressure of GCV.
对5例接受过更昔洛韦(GCV)治疗的巨细胞病毒(CMV)视网膜炎艾滋病患者在接受西多福韦(CDV)治疗期间进行连续采血,以检测CMV载量以及UL97和UL54基因的基因组成变化。CDV既未降低血液中的CMV载量,也未在治疗期间阻止其定量复发。这些效应无法通过UL54中最初存在或出现的与CDV相关的耐药性突变来解释。在2例患者中,在开始使用CDV时就存在对GCV的UL97基因型耐药,涉及L595S突变或氨基酸590 - 603缺失,并且在这2例患者中,在CDV治疗期间CMV毒株均出现了野生型UL97序列的重新增殖。这些数据与含有UL97突变的GCV耐药毒株比其野生型对应毒株适应性更差,因此仅在GCV的选择压力下才能持续存在的观点一致。